People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

A young man’s undiagnosed acromegaly leads to severe cardiac complications, highlighting the genetic links and diagnostic challenges of this rare condition.

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting ...

Paltusotine is an orally administered small molecule nonpeptide somatostatin receptor type 2 agonist. The FDA has accepted the NDA for paltusotine for the treatment and long-term maintenance of ...

Crinetics is seeking to change the way acromegaly is treated. Ahead of its hopes for a 2025 U.S. drug launch, the biotech is looking to spread awareness about how to treat the condition ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...

A machine learning model was more accurate than 12 experienced endocrinologists in identifying adults with acromegaly based on voice recordings, according to findings published in The Journal of ...

The randomized, placebo-controlled PATHFNDR-2 study included 111 patients with acromegaly who had elevated IGF-1 levels and were treatment naïve.

Standing 8'1" tall, Morteza Mehrzad -- who has acromegaly -- is the second-tallest man in the world and the tallest athlete to ever compete in a Paralympic Games.